Whistleblower sues Pfizer over Lipitor

There's nothing like a whistleblower lawsuit to get a company riled. A former Pfizer exec has accused the company of using continuing medical education as stealth marketing for its cholesterol drug Lipitor. Filed in 2004, the suit has been under seal as the feds decided whether to prosecute it themselves. They didn't, so Pfizer was officially served yesterday.

The company emphasized the feds' decision not to intervene in its denial of all the charges. "We believe that our sales and marketing practices are solely based on our prescription information" as approved by the FDA, Pfizer said. That may be so. But the government has chosen not to intervene before in cases that ended up with huge fines against drug makers.

- read the report from the Wall Street Journal

Related Articles:
Pfizer armed and ready for Lipitor fight. Report
Generic battle looms for Lipitor. Report
Investors cheer Lipitor patent decision. Report

Suggested Articles

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.